MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
Candel Therapeutics, Inc. (NASDAQ: CADL)*
Organization & Developments: Candel Therapeutics
Parents
Candel Therapeutics, Inc. (NASDAQ: CADL)*
Children
*Candel Therapeutics, Inc. is a late clinical-stage company developing oncolytic viral immunotherapies.
2022: Candel Therapeutics (CADL) Investor Presentation - Slideshow_seekingalpha.com
2023: Candel shares surge as pancreatic cancer candidate gets FDA fast track status_seekingalpha.com
2024: Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer
2024: Candel Therapeutics stock jumps as pancreatic cancer treatment shows promise
2024: Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think
2024: Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
2024: Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight_seekingalpha.com
2025: Candel Therapeutics: CAN-2409's Promising Progress Deserves An Upgrade
2025: FDA Fast-Tracks Revolutionary Prostate Cancer Therapy Showing 80% Complete Response Rate
Jumps
Finance & Acquisitions: Candel Therapeutics
Key People: Candel Therapeutics